AstraZeneca to receive up to $400 million to co-develop Parkinson’s drug

News

Author: Parkinson's Life editorsPublished: 31 August 2017

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

AstraZeneca and Takeda lead

AstraZeneca is to receive up to $400 million from Takeda Pharmaceutical after agreeing a deal to co-develop an early-stage medicine for Parkinson’s disease.

The drug, MEDI1341, is an antibody treatment and is due to enter phase I clinical trials later this year.

Mene Pangalos, executive vice president of AstraZeneca, said: “By combining our scientific expertise and sharing the risks and cost of development, we hope to accelerate the advancement of MEDI1341 as a promising new approach to support the treatment of people with Parkinson’s disease around the world.”

The two companies will share future development and commercialisation costs for MEDI1341 equally, in addition to future revenues.

Go Back

Share this story

Comments


Related articles


Popping for Parkinson's class

Health & Fitness

The body-popping dance class that helps people “forget” they have Parkinson’s

Hip-hop dance classes that could reduce Parkinson’s symptoms

READ MORE
Work and Parkinson's

Episodes

Podcast: What’s it like managing your working life with Parkinson’s?

Our guests reflect on work life with Parkinson's

READ MORE
Maura Ward

Interviews

Globetrotting with Parkinson’s: ‘a wonderful world waiting to be explored’

Maura Ward shares her top tips for travelling with Parkinson’s

READ MORE